Rekah Pharmaceutical Industry Ltd. (TLV:REKA)
Israel · Delayed Price · Currency is ILS · Price in ILA 1,231.00
0.00 (0.00%)
Feb 17, 2026, 5:24 PM IDT
TLV:REKA Income Statement
Financials in millions ILS. Fiscal year is January - December.
Millions ILS. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 300.24 | 321.71 | 321.66 | 292.39 | 263.95 | 265.47 | |
Revenue Growth (YoY) | -9.46% | 0.01% | 10.01% | 10.78% | -0.57% | 35.10% |
Cost of Revenue | 227.56 | 249.76 | 241.46 | 213.69 | 198.79 | 196.83 |
Gross Profit | 72.69 | 71.95 | 80.2 | 78.71 | 65.16 | 68.64 |
Selling, General & Admin | 72.13 | 73.71 | 71.04 | 60.45 | 49.62 | 46.2 |
Research & Development | 4.4 | 4.07 | 3.78 | 3.23 | 2.08 | 1.54 |
Other Operating Expenses | 24.26 | 1.51 | 2.48 | 1.77 | 0.55 | 0.01 |
Operating Expenses | 100.79 | 79.29 | 77.3 | 65.46 | 52.25 | 47.75 |
Operating Income | -28.1 | -7.34 | 2.91 | 13.25 | 12.91 | 20.89 |
Interest Expense | -5.72 | -6.71 | -8.29 | -5.65 | -5.63 | -5.81 |
Interest & Investment Income | 0.44 | 0.36 | 0.71 | 0.04 | 0.07 | 0.19 |
Earnings From Equity Investments | -0.08 | 0.01 | -0.22 | - | -0.13 | -0.64 |
Currency Exchange Gain (Loss) | 0.04 | 0.04 | -0.32 | 0.14 | -0.79 | -0.38 |
Other Non Operating Income (Expenses) | -0.77 | -0.77 | -1.29 | -0.83 | 0.06 | -0.26 |
EBT Excluding Unusual Items | -34.19 | -14.4 | -6.5 | 6.96 | 6.48 | 13.99 |
Gain (Loss) on Sale of Investments | -0.02 | -0.02 | 0.02 | -0.02 | 1.19 | 0.14 |
Gain (Loss) on Sale of Assets | 23.71 | 23.71 | 0.05 | 0 | 0.05 | 0.03 |
Other Unusual Items | -0.76 | -1.36 | -0.62 | -6.59 | - | - |
Pretax Income | -11.26 | 7.93 | -7.05 | 0.36 | 7.71 | 14.16 |
Income Tax Expense | 2.85 | 1.72 | -0.14 | 2.4 | 1.1 | 3.36 |
Earnings From Continuing Operations | -14.11 | 6.21 | -6.91 | -2.04 | 6.61 | 10.8 |
Net Income to Company | -14.11 | 6.21 | -6.91 | -2.04 | 6.61 | 10.8 |
Minority Interest in Earnings | - | - | 0 | 0 | 0.01 | - |
Net Income | -14.11 | 6.21 | -6.91 | -2.04 | 6.62 | 10.8 |
Net Income to Common | -14.11 | 6.21 | -6.91 | -2.04 | 6.62 | 10.8 |
Net Income Growth | - | - | - | - | -38.65% | 170.81% |
Shares Outstanding (Basic) | 12 | 11 | 11 | 11 | 11 | 11 |
Shares Outstanding (Diluted) | 12 | 11 | 11 | 11 | 11 | 11 |
Shares Change (YoY) | 4.25% | - | - | - | - | - |
EPS (Basic) | -1.21 | 0.54 | -0.61 | -0.18 | 0.58 | 0.95 |
EPS (Diluted) | -1.21 | 0.54 | -0.61 | -0.18 | 0.58 | 0.95 |
EPS Growth | - | - | - | - | -38.65% | 170.81% |
Free Cash Flow | 14.61 | 17.85 | 16.86 | 32.07 | 7.68 | -7.35 |
Free Cash Flow Per Share | 1.25 | 1.56 | 1.48 | 2.81 | 0.67 | -0.64 |
Dividend Per Share | - | - | - | - | 0.868 | - |
Gross Margin | 24.21% | 22.36% | 24.93% | 26.92% | 24.69% | 25.86% |
Operating Margin | -9.36% | -2.28% | 0.90% | 4.53% | 4.89% | 7.87% |
Profit Margin | -4.70% | 1.93% | -2.15% | -0.70% | 2.51% | 4.07% |
Free Cash Flow Margin | 4.87% | 5.55% | 5.24% | 10.97% | 2.91% | -2.77% |
EBITDA | -4.92 | 17.31 | 26.03 | 40.73 | 35.77 | 40.61 |
EBITDA Margin | -1.64% | 5.38% | 8.09% | 13.93% | 13.55% | 15.30% |
D&A For EBITDA | 23.19 | 24.65 | 23.12 | 27.48 | 22.86 | 19.71 |
EBIT | -28.1 | -7.34 | 2.91 | 13.25 | 12.91 | 20.89 |
EBIT Margin | -9.36% | -2.28% | 0.90% | 4.53% | 4.89% | 7.87% |
Effective Tax Rate | - | 21.72% | - | 672.27% | 14.21% | 23.73% |
Advertising Expenses | - | 2.51 | 3.16 | 1.3 | 1.63 | 1.36 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.